View in EDS

Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.

Saved in:

Bibliographic Details
Title:	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
Authors:	Wykoff CC; Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas. Electronic address: charleswyckoff@gmail.com., Rosenfeld PJ; University of Miami Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida., Waheed NK; Tufts Medical Center, Boston, Massachusetts., Singh RP; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio., Ronca N; Apellis Pharmaceuticals, Leominster, Massachusetts., Slakter JS; New York University School of Medicine, New York, New York., Staurenghi G; University of Milan-Bicocca: Universita degli Studi di Milano-Bicocca, Milan, Italy., Monés J; Barcelona Macula Foundation, Barcelona, Spain., Baumal CR; Tufts Medical Center, Boston, Massachusetts., Saroj N; Principal, All Eyes Consulting, LLC, New York, New York., Metlapally R; Apellis Pharmaceuticals, Leominster, Massachusetts., Ribeiro R; Apellis Pharmaceuticals, Leominster, Massachusetts.
Source:	Ophthalmology [Ophthalmology] 2021 Sep; Vol. 128 (9), pp. 1325-1336. Date of Electronic Publication: 2021 Mar 10.
Publication Type:	Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1549-4713
DOI:	10.1016/j.ophtha.2021.02.025